apple
- 25 Mar 2004 20:47
DSTOREY9916
- 16 Sep 2004 14:09
- 111 of 1451
And now heading south, are well!!
DSTOREY9916
- 16 Sep 2004 14:55
- 112 of 1451
Looks as those all that activity has come to a grinding halt!!
So should sp retreat be a further buying opportunity or was this merely a false dawn?
robstuff
- 16 Sep 2004 16:13
- 113 of 1451
It's Bid Speculation and why not at this price, someones bought a stake and we'll find out over next few days who, and then we should see some price improvement, and maybe a bid? Do the Majority s'holders - kingsman and family still have overall majority control? It would have to be an agreed bid I think.
apple
- 17 Sep 2004 09:48
- 114 of 1451
robstuff, what bid speculation?
It seems to be up because of a licence aggreement.
17/09/04 07:00 License Agreement RNS
It looks like the big buyer knew about it 2 days ago, giving them an unfair advantage.
hlyeo98
- 17 Sep 2004 11:24
- 115 of 1451
OXFORD BIOMEDICA SIGNS LICENSE AGREEMENT WITH MASSACHUSETTS GENERAL HOSPITAL, BOSTON UNIVERSITY AND DANA-FARBER CANCER INSTITUTE
Oxford BioMedica (LSE: OXB), the cancer and neurobiological gene therapy company, announced today that it has signed an agreement with Massachusetts General Hospital, Boston University and Dana-Farber Cancer Institute extending the field of Oxford BioMedicas exclusive access to the family of cytochrome P450 enzymes in cancer gene therapy. The P450 enzyme is used in Oxford BioMedicas novel cancer gene therapy product, MetXia. The extension of the license covers the development of MetXia as a treatment for pancreatic cancer.
Under a separate agreement, Massachusetts General Hospital, Boston University and Dana-Farber Cancer Institute have subscribed for a total of 352,887 ordinary shares of 1p each at 15.78 pence per share.
The P450 enzyme is naturally expressed in the liver and activates the chemotherapeutic drug cyclophosphamide. By delivering a specific P450 gene, MetXia promotes activation of cyclophosphamide directly in the tumour and thereby enhances its potency as an anti-tumour treatment. Oxford BioMedica licensed the rights to the P450 enzyme for cancer gene therapy from Massachusetts General Hospital, Boston University and Dana-Farber Cancer Institute in 1997 and extended the agreement previously in 2000.
Oxford BioMedica has demonstrated proof of concept with MetXia in two Phase I/II trials in patients with accessible tumours, primarily in breast cancer. In April 2004, the Company reported that recruitment had started in a Phase I trial, rolling into a Phase II trial in patients with pancreatic cancer. The safety stage of this trial is on-track to complete by the end of the year.
Janus
- 17 Sep 2004 16:09
- 116 of 1451
Oxford Biomedica PLC
17 September 2004
Oxford BioMedica plc (the 'Company')
Notification of Major Interests in Shares
The Company has received two notifications from Calyon Corporate and Investment
Bank on 16 & 17 September 2004 on behalf of Credit Agricole Cheuvreux
International Ltd.
The first informing it that they have an interest in 18,702,000 shares
representing 5.03% of the issued share capital and the second informing it that
they now have and interest in 18,552,000 shares representing 4.99% of the issued
shares capital of the Company which currently stands at 371,961,736 shares.
Andrew Wood
Chief Financial Officer
Tel 01865 783000
DSTOREY9916
- 17 Sep 2004 16:32
- 117 of 1451
Very interesting stuff! Looks as though big boys are positioning themselves for future announcements/sp re-valuation.
apple
- 17 Sep 2004 17:52
- 118 of 1451
Makes me glad that I left my profit in after the previous rise, pity that I didn't leave it all in.
:-)
So the big buyer I saw on Wednesday was Credit Agricole Cheuvreux International Ltd.
DSTOREY9916
- 18 Sep 2004 10:17
- 119 of 1451
Apple, you want too hazard a guess as too what price OXB will reach year end if newsflow is as predicted?
hlyeo98
- 19 Sep 2004 19:50
- 120 of 1451
can u guess?
apple
- 20 Sep 2004 15:17
- 121 of 1451
I wouldn't dare!
DSTOREY9916
- 21 Sep 2004 00:50
- 122 of 1451
Well here goes for me;
1. No RNS 20p by month end.
2. RNS too reach yr high of 39p min.
3. Multiple RNS it will rocket!
4. Hostile bid upwards of 50p, which would be a steal.
IMHO
apple
- 22 Sep 2004 22:57
- 123 of 1451
Janus
- 23 Sep 2004 07:38
- 124 of 1451
Yes these folks are active in PRM as well, coincidence ?
apple
- 01 Oct 2004 11:40
- 125 of 1451
On the up again!
hlyeo98
- 04 Oct 2004 13:16
- 126 of 1451
18p now...on the up
apple
- 04 Oct 2004 14:52
- 127 of 1451
Now UP 10.45%
There must be some news coming?
Tradx
- 04 Oct 2004 15:10
- 128 of 1451
apple,
can you hazard a guess at what's driving this back up..??
regards
T..
erenr
- 04 Oct 2004 15:11
- 129 of 1451
img src="http://www.moneyam.com/cache/graph.php?size=Big&movingAverageString=%2C50%2C200&enableRSI=true&modeMA=Simple&movingAverageString1=&startDate=01%2F10%2F04&enableMA=true&period=2D&epic=%60UKX&periodRSI1=">
apple
- 04 Oct 2004 15:30
- 130 of 1451
Tradx
Like I said there must be some news coming, I suppose that other people know before we do.
This company has so many drugs that there will be lots of news & any 1 of them could transform the company.